uniQure N.V (UQ1) - Cash Flow Conversion Efficiency
Based on the latest financial reports, uniQure N.V (UQ1) has a cash flow conversion efficiency ratio of -0.256x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-38.24 Million ≈ $-44.71 Million USD) by net assets (€149.34 Million ≈ $174.60 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See uniQure N.V net asset quality index to measure how much of total assets are equity-financed.
uniQure N.V - Cash Flow Conversion Efficiency Trend (2016–2025)
This chart illustrates how uniQure N.V's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check uniQure N.V cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
uniQure N.V Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of uniQure N.V ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Northking Information Technology Co
SHE:002987
|
0.027x |
|
The Wendy’s Co
NASDAQ:WEN
|
0.590x |
|
MY EG Services Bhd
KLSE:0138
|
0.068x |
|
Paramount Group Inc
NYSE:PGRE
|
0.001x |
|
Great Wall Enterprise Co Ltd
TW:1210
|
0.044x |
|
Resilient Property Income Fund Ltd
JSE:RES
|
0.028x |
|
Jinlongyu Group Co Ltd Class A
SHE:002882
|
0.066x |
|
Dar Global Plc
LSE:DAR
|
0.112x |
Annual Cash Flow Conversion Efficiency for uniQure N.V (2016–2025)
The table below shows the annual cash flow conversion efficiency of uniQure N.V from 2016 to 2025. For the full company profile with market capitalisation and key ratios, see market value of uniQure N.V.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | €198.90 Million ≈ $232.54 Million |
€-177.96 Million ≈ $-208.06 Million |
-0.895x | -103.31% |
| 2024-12-31 | €-6.75 Million ≈ $-7.89 Million |
€-182.73 Million ≈ $-213.63 Million |
27.063x | +3951.28% |
| 2023-12-31 | €207.67 Million ≈ $242.79 Million |
€-145.93 Million ≈ $-170.61 Million |
-0.703x | -130.59% |
| 2022-12-31 | €476.01 Million ≈ $556.50 Million |
€-145.06 Million ≈ $-169.59 Million |
-0.305x | -163.05% |
| 2021-12-31 | €595.78 Million ≈ $696.52 Million |
€287.96 Million ≈ $336.65 Million |
0.483x | +187.44% |
| 2020-12-31 | €243.91 Million ≈ $285.15 Million |
€-134.83 Million ≈ $-157.63 Million |
-0.553x | -80.96% |
| 2019-12-31 | €323.06 Million ≈ $377.69 Million |
€-98.68 Million ≈ $-115.37 Million |
-0.305x | +27.85% |
| 2018-12-31 | €179.61 Million ≈ $209.98 Million |
€-76.04 Million ≈ $-88.90 Million |
-0.423x | +41.14% |
| 2017-12-31 | €89.36 Million ≈ $104.47 Million |
€-64.27 Million ≈ $-75.14 Million |
-0.719x | +36.60% |
| 2016-12-31 | €63.63 Million ≈ $74.39 Million |
€-72.19 Million ≈ $-84.40 Million |
-1.134x | -- |
About uniQure N.V
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases in the United States. The company offers HEMGENIX that allows people living with hemophilia B to produce factor IX, which can lower the risk of bleeding. Its lead product candidate is AMT-130, a gene therapy candidate, which is in Phase I/II clinical study for the treatment of Huntington's disease. Th… Read more